phone icon  Int'l : +1-503-894-6022
Allied Market Research
0
Shopping Cart is Empty..
$ 0

Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices that has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic cases. However, factors such as strict regulatory impositions, inadequate reimbursement options for CGM, lack of accurate results and cost of the CGMs are restraining the market growth.The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020, growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations, namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM.

Global CGM market is segmented based on application as home settings, diagnostics and hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020.

North America is the maximum revenue-generating segment across the globe, mainly due to rapid acceptance of innovative technology, well-penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to large patient pool, geographical expansion of market players, increase in income levels and improved living standards of the people.

Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategies adopted by the market players across geographies are Collaborations, Product launches and approvals. Collaborations in the regions focus on distribution and commercialization of the devices.

Continuous Glucose Monitoring Market brings good news for medical device manufacturers.

KEY BENEFITS

  • The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more
  • Market is forecast for the period 2013 - 2020 with market revenues for 2 historic years of 2010 and 2012
  • Identification and analysis of key pockets of investment for CGM manufacturers
  • Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market
  • Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario
  • The report identifies and profiles key market participants that would drive innovation in the CGM market

KEY MARKET SEGMENTS

GLOBAL MARKET, BY DEVICES

  • Transmitter and Receivers
  • Sensors
  • Insulin Pump

GLOBAL MARKET, BY APPLICATION

  • Diagnostics/Clinics
  • Hospitals
  • Home Settings

GLOBAL MARKET, BY AGE

  • Children and Teens
  • Youth
  • Middle, Elderly and Aged

GLOBAL MARKET, BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • Row

KEY AUDIENCES

  • Medical Devices Manufacturers
  • Research Institutions
  • Healthcare Institutions
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1 INTRODUCTION

1.1 Objectives and Scope
1.2 Report Description
1.3 Key Benefits of the Report
1.4 Research Methodology

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 GLOBAL CONTINUOUS GLUCOSE MONITORS MARKET OVERVIEW

3.1 Healthcare Expenditure on Diabetes Worldwide
3.2 Type-1 Diabetics to Remain Key Target for CGM Market

3.2.1 Type-1 Diabetes

3.2.1.1 Type-1 Diabetes in Young People

3.2.2 Type-2 Diabetes

3.2.2.1 Type-2 Diabetes in Young People

3.2.3 Gestational Diabetes
3.2.4 Other Types of Diabetes

3.3 Market Intelligence

3.3.1 Top Factors Impacting Continuous Glucose Monitors Market, 2013-2020

3.3.1.1 Fda Approval of Artificial Pancreas
3.3.1.2 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.3.1.3 Rise in Incidences of Diabetes Cases Globally
3.3.1.4 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.3.1.5 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.3.1.6 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM
3.3.1.7 Strict Regulatory Impositions
3.3.1.8 Increase in Awareness Among Developing and Underdeveloped Economies

3.3.2 Top Three Winning Strategies in the Continuous Glucose Monitors Market
3.3.2.1 Global Market Players Positioning
3.3.3 Top Investment Pockets in Continuous Glucose Monitors Market

3.3.3.1 Continuous Glucose Monitors Market – by Device
3.3.3.2 Continuous Glucose Monitors Market – by Applications
3.3.3.3 Continuous Glucose Monitors Market – by Geography

3.4 Regulations
3.5 Reimbursement Scenario
3.6 Market Dynamics

3.6.1 Drivers

3.6.1.1 Convenience Offered by CGM Over Self Monitoring Glucose Devices
3.6.1.2 FDA Approval of Artificial Pancreas Enables Closing the Loop and Overcomes the Limitation of Current Diabetes Care Management System
3.6.1.3 Earlier Detection of the Hypo and Hyperglycemic Events by CGM
3.6.1.4 Rise in Incidences of Diabetes Cases Globally
3.6.1.5 Increase in Awareness Among the Population in Developing and Underdeveloped Economies

3.6.2 Restraints

3.6.2.1 Strict Regulatory Impositions
3.6.2.2 Inadequate Reimbursement Options for CGM Serve as Barriers for its Adoption
3.6.2.3 Accuracy and Cost Acts as a Hindrance in Continuing Use of CGM

3.6.3 Market Opportunity

3.6.3.1 Growth in Emerging Market

3.6.4 Winning Strategies for Mncs in Emerging Markets

3.6.4.1 Tailoring the Existing Products to the Local Market Needs
3.6.4.2 Adoption of a Proactive Hybrid Model Rather Than Distributor Management
3.6.4.3 Service Rendered Makes a Difference
3.6.4.4 Partnership and Acquisition Key to Enhance Reach and Market Position
3.6.4.5  Adopting An Emerging-Market Attitude

Chapter: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY DEVICES

4.1 Transmitter and Receivers
4.2 Sensors

4.2.1 Market Trend

4.2.1.1 Non-Invasive Glucose Sensors
4.2.1.2 Subcutaneous Sensors (Minimally Invasive Sensors)
4.2.1.3 Conventional Technology – Holter-Type Retrospective Sensors
4.2.1.4 Advanced Technology – Real-Time Sensors

4.3 Insulin Pump

4.3.1 Advantages of Insulin Pump
4.3.2 Disadvantages of Insulin Pump
4.3.3 Market Trend

Chapter: 5 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET - BY APPLICATION

5.1 Diagnostics/Clinics
5.2 Hospitals
5.3 Home Settings
5.4 Role of CGM in Private Practice

5.4.1 Team Members
5.4.2 Clinical Space
5.4.3 Scheduling
5.4.4 Keeping the Patients Informed

Chapter: 6 CONTINUOUS GLUCOSE MONITORING SYSTEM MARKET – BY AGE

6.1 Children and Teens
6.2 Youth
6.3 Middle Elderly and Aged

Chapter: 7 CGM SYSTEMS MARKET BY GEOGRAPHY

7.1 North America
7.2 Europe
7.2.1 Financial Cost Incurred
7.3 Asia Pacific
7.4 Row

Chapter: 8 COMPANY PROFILES

8.1 Medtronic Inc.

8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Business Performance
8.1.4 Strategic Moves and Developments

8.1.4.1 Principal Strategies: Product Launch
8.1.4.2 Secondary Strategies: Approval
8.1.4.3 Other Strategies: Collaboration

8.1.5 SWOT Analysis & Strategic Conclusions

8.2 Dexcom Inc.

8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Business Performance
8.2.4 Strategic Moves and Developments

8.2.4.1 Principal Strategies: Agreement/Partnership
8.2.4.2 Secondary Strategies: Acquisition

8.2.5 SWOT Analysis & Strategic Conclusions

8.3 Novo Nordisk

8.3.1 Company Profile
8.3.2 Company Snapshot
8.3.3 Strategic Moves and Developments
8.3.4 SWOT Analysis & Strategic Conclusions

8.4 Spring Health Solution Ltd

8.4.1 Company Profile
8.4.2 Company Snapshot
8.4.3 Strategic Moves and Developments

8.4.3.1 Principal Strategies

8.4.4 SWOT Analysis & Strategic Conclusions

8.5 Roche

8.5.1 Company Profile
8.5.2 Company Snapshot
8.5.3 Strategic Moves and Developments
8.5.4 SWOT Analysis & Strategic Conclusions

8.6 Animas Corporation

8.6.1 Company Profile
8.6.2 Company Snapshot
8.6.3 Strategic Moves and Developments

8.6.3.1 Principal Strategies

8.6.4 SWOT Analysis & Strategic Conclusions

8.7 Ypsomed AG

8.7.1 Company Profile
8.7.2 Company Snapshot
8.7.3 Strategic Moves and Developments

8.7.3.1 Principal Strategies: Product Expansion
8.7.3.2 Secondary Strategies: New Subsidiary
8.7.3.3 Other Strategies: Acquisition and Agreements

8.7.4 SWOT Analysis & Strategic Conclusions

8.8 Insulet Corporation

8.8.1 Company Profile
8.8.2 Company Snapshot
8.8.3 Strategic Moves and Developments

8.8.3.1 Principal Strategies

8.8.4 SWOT Analysis & Strategic Conclusions

 

LIST OF TABLES

TABLE 1 FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (AS OF MARCH 2013)
TABLE 2 FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (AS OF MARCH 2013)
TABLE 3 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY PRODUCT CATEGORY, 2011-2020, ($MILLION)
TABLE 4 GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 5 GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 6 GLOBAL CGM INSULIN PUMP MARKET BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 7 GLOBAL CGM MARKET BY APPLICATION SEGMENTS, 2011 - 2020, ($MILLION)
TABLE 8 GLOBAL CGM MARKET IN DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 9 GLOBAL CGM MARKET IN HOSPITALS, BY GEOGRAPHY, 2011 - 2020, ($THOUSAND)
TABLE 10 GLOBAL CGM MARKET IN HOME SETTINGS, BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 11 GLOBAL CGM MARKET BY AGE, 2011 - 2020, ($MILLION)
TABLE 12 TYPE-1 DIABETES (0-14 YEARS), 2013
TABLE 13 FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2013 AND 2020
TABLE 14 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS BY GEOGRAPHY, 2011 - 2020, ($MILLION)
TABLE 15 THE PREVALENCE OF DIABETES IN THE ADULT POPULATION ACROSS THE U.K. IN 2011
TABLE 16 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
TABLE 17 PREVALENCE ESTIMATES OF DIABETES, 2013 & 2035
TABLE 18 PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, AFRICA REGION
TABLE 19 MEDTRONIC BUSINESS SNAPSHOT
TABLE 20 DEXCOM INC. BUSINESS SNAPSHOT
TABLE 21 NOVA NORDISK BUSINESS SNAPSHOT
TABLE 22 SPRING HEALTH SOLUTION LTD BUSINESS SNAPSHOT
TABLE 23 ROCHE BUSINESS SNAPSHOT
TABLE 24 ANIMAS CORPORATION BUSINESS SNAPSHOT
TABLE 25 YPSOMED AG BUSINESS SNAPSHOT
TABLE 26 INSULET CORPORATION BUSINESS SNAPSHOT


LIST OF FIGURES

FIG. 1 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, BY GEOGRAPHY ($BILLION)
FIG. 2 GLOBAL HEALTH EXPENDITURE DUE TO DIABETES, 20-79 YEARS ($BILLION)
FIG. 3 TREATMENT OF DIABETES, 2011
FIG. 4 SIMILARITIES IN CAUSE OF PRE-DIABETES AND TYPE-2 DIABETES
FIG. 5 CGM ADOPTION BY DIFFERENT TYPES OF DIABETES PATIENTS
FIG. 6 PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY, (THOUSAND)
FIG. 7 GLOBAL PREVALENCE OF TYPE-2 DIABETES IN 2000 & ESTIMATED PREVALENCE IN 2030
FIG. 8 TOP FACTORS IMPACTING CGM MARKET, 2013-2020
FIG. 9 TOP WINNING STRATEGY IN CGM MARKET, 2010 TO 2013 (SEPTEMBER)
FIG. 10 TOP WINNING STRATEGY IN CGM MARKET BY YEAR
FIG. 11 GLOBAL MARKET PLAYERS POSITIONING
FIG. 12 TOP INVESTMENT POCKETS IN CGM DEVICE MARKETS
FIG. 13 TOP INVESTMENT POCKETS IN CGM APPLICATION MARKETS
FIG. 14 TOP INVESTMENT POCKETS IN CGM GEOGRAPHY MARKETS
FIG. 15 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 16 GDP PER CAPITA IN EMERGING ECONOMIES
FIG. 17 EMERGING MARKET CAPITALIZATION STRATEGIES
FIG. 18 GLOBAL CGM MARKET AMONG CHILDREN, 2011-2020, ($MILLION)
FIG. 19 GLOBAL CGM MARKET AMONG TEENS, 2011-2020, ($MILLION)
FIG. 20 GLOBAL CGM MARKET AMONG YOUTH, 2011-2020, ($MILLION)
FIG. 21 GLOBAL CGM MARKET AMONG MIDDLE ELDERLY, 2011-2020, ($MILLION)
FIG. 22 GLOBAL CGM MARKET AMONG AGED, 2011-2020, ($MILLION)
FIG. 23 NORTH AMERICA CGM MARKET, 2013-2020, ($MILLION)
FIG. 24 CASES OF DIABETES BY AGES IN NAC (1000S) (2013 E)
FIG. 25 EUROPE CGM MARKET, 2013-2020, ($MILLION)
FIG. 26 CASES OF DIABETES BY AGES IN EUROPE (1000S) (2013 E)
FIG. 27 ASIA PACIFIC CGM MARKET, 2013-2020, ($MILLION)
FIG. 28 TOP 10 COUNTRIES WITH DIABETES INCIDENCES 2013 AND 2035
FIG. 29 ROW CGM MARKET, 2013-2020, ($MILLION)
FIG. 30 FINANCIAL REVENUES BY BUSINESS UNITS (2013)
FIG. 31 FINANCIAL REVENUES BY GEOGRAPHY (2013)
FIG. 32 FINANCIAL REVENUES BY GEOGRAPHY (2012)

The global continuous glucose monitors (CGM) market is at its emerging state. The market has witnessed launch of various continuous glucose monitoring devices in last 7 to 8 years with continuous improvement in technology. Furthermore, innovations are expected to translate the entire market scenario in the coming five to seven years. The open loop continuous glucose monitoring can now be regarded as closed with the introduction of artificial pancreas named MiniMed 530G with Enlite by Medtronic in September 2013. Launch of this product has taken diabetic care management to a next level. The market is overcoming several challenges towards the commercialization of closed loop CGMs due to significant focus on technological innovation. This is expected to take the concept of CGMs to a next level from research to large level adoption. Major factors driving the market growth are convenience offered by CGM over conventional glucose monitoring devices, earlier detection of the Hypo and Hyperglycemic events, global rise in incidences of diabetes cases, and awareness among global population.

This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
buy now

Discount will be applied in cart.
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Smart syringes can be defined as medical devices that are engineered with safety mechanisms to prevent the reuse of syringes and regulates unsafe injection practices.
    Jan 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Biosurgery products are used in various surgeries to minimize the intra and post-operative complications. Various synthetic and biologic products like anti-adhesive agents, hemostatic agents, surgical sealing agents, bone graft substitutes, and soft tissue management are utilized in surgeries for preventing excessive blood loss or providing adhesion or wound/tissue sealing, and repair of damaged or weakened tissues or bones of a body.
    Mar 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    In vitro diagnostics (IVD) is the technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues and other body fluids, which are derived from the human body to detect diseases, conditions and infections. The tests can be performed in stand-alone laboratory, hospital based laboratory and point of care. Some of the significant technologies incorporated in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology and mass spectrometry, which are used for test sample preparation.
    Feb 2016 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patient’s survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia).
    Feb 2016 | Price: $2500(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    The pacemaker is an artificial device implanted in the chest that generates low-energy electrical pulses to regulate the abnormal heart rhythm. Pacemakers are used in the medical conditions such as Arrhythmia, Atrial fibrillation, Heart block, and Long QT syndrome. The high prevalence of arrhythmia along with no precise therapy that regulate the cardiac rhythm have generated the need for pacemaker devices.
    Jul 2016 | View Details >>
  • ...
    Diabetes is a condition with abnormally high level of insulin in blood. Diabetes Drugs are used to treat diabetes mellitus by lowering the glucose levels in the blood. Type 1 Diabetes is a condition caused by the lack of insulin, whereas Type 2 Diabetes is a condition caused due to insulin resistance by cells.
    Jul 2016 | View Details >>
  • ...
    Protein kinase is an enzyme that shuffles protein structure by transferring phosphate collected from ATP(Adenosine Triphosphate) . Protein kinase help in regulating variety of cell functions such as cell cycle, cell differentiation, cell proliferation and apoptosis. These cell processes are used in regulating various cell activities in cancer. The global inhibitors market was valued at approximately $105 billion. Increase in incident of cancer diseases is driving the growth for kinase inhibitor market. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013.
    Jul 2016 | View Details >>
  • ...
    Lymphoma comprises of a diverse group of blood cancers with different causes and treatment pathways. It is mainly categorized into two forms i.e., Hodgkin Lymphoma and non-Hodgkin Lymphoma (NHL). According to the American Cancer Society (ACS), NHL is one of the most frequently diagnosed cancer in the U.S. that represent 4% of all types of cancers.
    Jul 2016 | View Details >>